The value of SPECT in detecting Alzheimer-type neurodegeneration in mild cognitive impairment

Flavio Nobili, Fabrizio De Carli, Giovanni B. Frisoni, Florence Portet, Frans Verhey, Guido Rodriguez, Anna Caroli, Jacques Touchon, Silvia Morbelli, Ugo P. Guerra, Barbara Dessi, Andrea Brugnolo, Pieter Jelle Visser

Research output: Chapter in Book/Report/Conference proceedingChapterAcademicpeer-review

Abstract

Despite brain perfusion SPECT with technetium radiopharmaceuticals has not been formally included among the biomarkers for the early diagnosis of Alzheimer's disease (AD), its worldwide availability and the large literature evidence in AD and related disorders still make of it a valid alternative to FDG-PET, wherever the latter is unavailable. In this article, baseline brain SPECT has been evaluated in 80 subjects presenting with a cognitive complaint who have been followed for a mean of about two years, when twelve patients developed AD-dementia (AD-D), nineteen showed significant memory decline (D), and forty-three had normal cognition assessment (stable: S), while six patients dropped-out. Volumetric Regions of Interest (VROI) analysis was performed in six associative cortical areas in each hemisphere. ANOVA for repeated measures showed significant effects for both the group (S, D, and AD-D; p < 0.004) and VROI (p < 0.0001) factors, with significant group region interaction (p < 0.01). At post-hoc comparison, hippocampal VROIs values were lower in AD-D than in D and S, while parietal VROIs values were lower in D and AD-D than in S. These four VROI significantly correlated with verbal delayed recall score at follow-up visit. Receiver operating characteristic (ROC) curves for the mean hippocampal VROI value showed 0.81 sensitivity with 0.86 specificity in separation of S + D from AD-D (p < 0.0001), and 0.69 sensitivity with 0.75 specificity in separation of S from D + AD-D (p < 0.0002). ROC curves for the mean parietal VROI value showed 0.62 sensitivity with 0.70 specificity in separation of S from D + AD-D (p < 0.0002). Baseline SPECT can support outcome prediction in subjects with MCI and assist clinicians in identifying MCI patients with biological signs of neurodegeneration of the AD-type in critical cortical areas.

Original languageEnglish
Title of host publicationHandbook of Imaging the Alzheimer Brain
EditorsJ. Wesson Ashford, Allyson Rosen, Maheen Adamson, Peter Bayley, Ansgar Furst, Osama Sabri, Sandra E. Black, Michael Weiner
Pages205-217
Number of pages13
DOIs
Publication statusPublished - 1 Dec 2011

Publication series

NameAdvances in Alzheimer's Disease
Volume2
ISSN (Print)2210-5727
ISSN (Electronic)2210-5735

Cite this

Nobili, F., De Carli, F., Frisoni, G. B., Portet, F., Verhey, F., Rodriguez, G., ... Visser, P. J. (2011). The value of SPECT in detecting Alzheimer-type neurodegeneration in mild cognitive impairment. In J. Wesson Ashford, A. Rosen, M. Adamson, P. Bayley, A. Furst, O. Sabri, S. E. Black, ... M. Weiner (Eds.), Handbook of Imaging the Alzheimer Brain (pp. 205-217). (Advances in Alzheimer's Disease; Vol. 2). https://doi.org/10.3233/978-1-60750-793-2-205
Nobili, Flavio ; De Carli, Fabrizio ; Frisoni, Giovanni B. ; Portet, Florence ; Verhey, Frans ; Rodriguez, Guido ; Caroli, Anna ; Touchon, Jacques ; Morbelli, Silvia ; Guerra, Ugo P. ; Dessi, Barbara ; Brugnolo, Andrea ; Visser, Pieter Jelle. / The value of SPECT in detecting Alzheimer-type neurodegeneration in mild cognitive impairment. Handbook of Imaging the Alzheimer Brain. editor / J. Wesson Ashford ; Allyson Rosen ; Maheen Adamson ; Peter Bayley ; Ansgar Furst ; Osama Sabri ; Sandra E. Black ; Michael Weiner. 2011. pp. 205-217 (Advances in Alzheimer's Disease).
@inbook{2d80de6e97b64e57839f7aec5cd94de0,
title = "The value of SPECT in detecting Alzheimer-type neurodegeneration in mild cognitive impairment",
abstract = "Despite brain perfusion SPECT with technetium radiopharmaceuticals has not been formally included among the biomarkers for the early diagnosis of Alzheimer's disease (AD), its worldwide availability and the large literature evidence in AD and related disorders still make of it a valid alternative to FDG-PET, wherever the latter is unavailable. In this article, baseline brain SPECT has been evaluated in 80 subjects presenting with a cognitive complaint who have been followed for a mean of about two years, when twelve patients developed AD-dementia (AD-D), nineteen showed significant memory decline (D), and forty-three had normal cognition assessment (stable: S), while six patients dropped-out. Volumetric Regions of Interest (VROI) analysis was performed in six associative cortical areas in each hemisphere. ANOVA for repeated measures showed significant effects for both the group (S, D, and AD-D; p < 0.004) and VROI (p < 0.0001) factors, with significant group region interaction (p < 0.01). At post-hoc comparison, hippocampal VROIs values were lower in AD-D than in D and S, while parietal VROIs values were lower in D and AD-D than in S. These four VROI significantly correlated with verbal delayed recall score at follow-up visit. Receiver operating characteristic (ROC) curves for the mean hippocampal VROI value showed 0.81 sensitivity with 0.86 specificity in separation of S + D from AD-D (p < 0.0001), and 0.69 sensitivity with 0.75 specificity in separation of S from D + AD-D (p < 0.0002). ROC curves for the mean parietal VROI value showed 0.62 sensitivity with 0.70 specificity in separation of S from D + AD-D (p < 0.0002). Baseline SPECT can support outcome prediction in subjects with MCI and assist clinicians in identifying MCI patients with biological signs of neurodegeneration of the AD-type in critical cortical areas.",
keywords = "Alzheimer's disease, amnestic MCI, brain SPECT, cognitive decline, non-amnestic MCI, Subjective cognitive impairment",
author = "Flavio Nobili and {De Carli}, Fabrizio and Frisoni, {Giovanni B.} and Florence Portet and Frans Verhey and Guido Rodriguez and Anna Caroli and Jacques Touchon and Silvia Morbelli and Guerra, {Ugo P.} and Barbara Dessi and Andrea Brugnolo and Visser, {Pieter Jelle}",
year = "2011",
month = "12",
day = "1",
doi = "10.3233/978-1-60750-793-2-205",
language = "English",
isbn = "9781607507925",
series = "Advances in Alzheimer's Disease",
pages = "205--217",
editor = "{Wesson Ashford}, J. and Allyson Rosen and Maheen Adamson and Peter Bayley and Ansgar Furst and Osama Sabri and Black, {Sandra E.} and Michael Weiner",
booktitle = "Handbook of Imaging the Alzheimer Brain",

}

Nobili, F, De Carli, F, Frisoni, GB, Portet, F, Verhey, F, Rodriguez, G, Caroli, A, Touchon, J, Morbelli, S, Guerra, UP, Dessi, B, Brugnolo, A & Visser, PJ 2011, The value of SPECT in detecting Alzheimer-type neurodegeneration in mild cognitive impairment. in J Wesson Ashford, A Rosen, M Adamson, P Bayley, A Furst, O Sabri, SE Black & M Weiner (eds), Handbook of Imaging the Alzheimer Brain. Advances in Alzheimer's Disease, vol. 2, pp. 205-217. https://doi.org/10.3233/978-1-60750-793-2-205

The value of SPECT in detecting Alzheimer-type neurodegeneration in mild cognitive impairment. / Nobili, Flavio; De Carli, Fabrizio; Frisoni, Giovanni B.; Portet, Florence; Verhey, Frans; Rodriguez, Guido; Caroli, Anna; Touchon, Jacques; Morbelli, Silvia; Guerra, Ugo P.; Dessi, Barbara; Brugnolo, Andrea; Visser, Pieter Jelle.

Handbook of Imaging the Alzheimer Brain. ed. / J. Wesson Ashford; Allyson Rosen; Maheen Adamson; Peter Bayley; Ansgar Furst; Osama Sabri; Sandra E. Black; Michael Weiner. 2011. p. 205-217 (Advances in Alzheimer's Disease; Vol. 2).

Research output: Chapter in Book/Report/Conference proceedingChapterAcademicpeer-review

TY - CHAP

T1 - The value of SPECT in detecting Alzheimer-type neurodegeneration in mild cognitive impairment

AU - Nobili, Flavio

AU - De Carli, Fabrizio

AU - Frisoni, Giovanni B.

AU - Portet, Florence

AU - Verhey, Frans

AU - Rodriguez, Guido

AU - Caroli, Anna

AU - Touchon, Jacques

AU - Morbelli, Silvia

AU - Guerra, Ugo P.

AU - Dessi, Barbara

AU - Brugnolo, Andrea

AU - Visser, Pieter Jelle

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Despite brain perfusion SPECT with technetium radiopharmaceuticals has not been formally included among the biomarkers for the early diagnosis of Alzheimer's disease (AD), its worldwide availability and the large literature evidence in AD and related disorders still make of it a valid alternative to FDG-PET, wherever the latter is unavailable. In this article, baseline brain SPECT has been evaluated in 80 subjects presenting with a cognitive complaint who have been followed for a mean of about two years, when twelve patients developed AD-dementia (AD-D), nineteen showed significant memory decline (D), and forty-three had normal cognition assessment (stable: S), while six patients dropped-out. Volumetric Regions of Interest (VROI) analysis was performed in six associative cortical areas in each hemisphere. ANOVA for repeated measures showed significant effects for both the group (S, D, and AD-D; p < 0.004) and VROI (p < 0.0001) factors, with significant group region interaction (p < 0.01). At post-hoc comparison, hippocampal VROIs values were lower in AD-D than in D and S, while parietal VROIs values were lower in D and AD-D than in S. These four VROI significantly correlated with verbal delayed recall score at follow-up visit. Receiver operating characteristic (ROC) curves for the mean hippocampal VROI value showed 0.81 sensitivity with 0.86 specificity in separation of S + D from AD-D (p < 0.0001), and 0.69 sensitivity with 0.75 specificity in separation of S from D + AD-D (p < 0.0002). ROC curves for the mean parietal VROI value showed 0.62 sensitivity with 0.70 specificity in separation of S from D + AD-D (p < 0.0002). Baseline SPECT can support outcome prediction in subjects with MCI and assist clinicians in identifying MCI patients with biological signs of neurodegeneration of the AD-type in critical cortical areas.

AB - Despite brain perfusion SPECT with technetium radiopharmaceuticals has not been formally included among the biomarkers for the early diagnosis of Alzheimer's disease (AD), its worldwide availability and the large literature evidence in AD and related disorders still make of it a valid alternative to FDG-PET, wherever the latter is unavailable. In this article, baseline brain SPECT has been evaluated in 80 subjects presenting with a cognitive complaint who have been followed for a mean of about two years, when twelve patients developed AD-dementia (AD-D), nineteen showed significant memory decline (D), and forty-three had normal cognition assessment (stable: S), while six patients dropped-out. Volumetric Regions of Interest (VROI) analysis was performed in six associative cortical areas in each hemisphere. ANOVA for repeated measures showed significant effects for both the group (S, D, and AD-D; p < 0.004) and VROI (p < 0.0001) factors, with significant group region interaction (p < 0.01). At post-hoc comparison, hippocampal VROIs values were lower in AD-D than in D and S, while parietal VROIs values were lower in D and AD-D than in S. These four VROI significantly correlated with verbal delayed recall score at follow-up visit. Receiver operating characteristic (ROC) curves for the mean hippocampal VROI value showed 0.81 sensitivity with 0.86 specificity in separation of S + D from AD-D (p < 0.0001), and 0.69 sensitivity with 0.75 specificity in separation of S from D + AD-D (p < 0.0002). ROC curves for the mean parietal VROI value showed 0.62 sensitivity with 0.70 specificity in separation of S from D + AD-D (p < 0.0002). Baseline SPECT can support outcome prediction in subjects with MCI and assist clinicians in identifying MCI patients with biological signs of neurodegeneration of the AD-type in critical cortical areas.

KW - Alzheimer's disease

KW - amnestic MCI

KW - brain SPECT

KW - cognitive decline

KW - non-amnestic MCI

KW - Subjective cognitive impairment

UR - http://www.scopus.com/inward/record.url?scp=84865410726&partnerID=8YFLogxK

U2 - 10.3233/978-1-60750-793-2-205

DO - 10.3233/978-1-60750-793-2-205

M3 - Chapter

SN - 9781607507925

T3 - Advances in Alzheimer's Disease

SP - 205

EP - 217

BT - Handbook of Imaging the Alzheimer Brain

A2 - Wesson Ashford, J.

A2 - Rosen, Allyson

A2 - Adamson, Maheen

A2 - Bayley, Peter

A2 - Furst, Ansgar

A2 - Sabri, Osama

A2 - Black, Sandra E.

A2 - Weiner, Michael

ER -

Nobili F, De Carli F, Frisoni GB, Portet F, Verhey F, Rodriguez G et al. The value of SPECT in detecting Alzheimer-type neurodegeneration in mild cognitive impairment. In Wesson Ashford J, Rosen A, Adamson M, Bayley P, Furst A, Sabri O, Black SE, Weiner M, editors, Handbook of Imaging the Alzheimer Brain. 2011. p. 205-217. (Advances in Alzheimer's Disease). https://doi.org/10.3233/978-1-60750-793-2-205